Tuesday, 16 Jul 2019

You are here

Cardiovascular Events: Allopurinol vs. Febuxostat

In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify. So this study by MaryAnn Zhang and co-authors from Brigham & Women’s Hospital and Boston University, Boston and The Seoul National University in Korea is an important piece of work to contribute to building a picture of the CV safety of febuxostat.

The authors used five years of US Medicare claims data to complete a cohort study of gout patients over 65 years who started on allopurinol or febuxostat. They included 24,900 febuxostat starters with 74,700 who started on allopurinol, a 1:3 match using propensity scoring. Propensity score matching is a method to try and match people for similar characteristics to reduce bias in studies.

They followed people for just over a year and found no difference in hazard ratios (HR) for the primary end point of myocardial infarction or stroke (HR 1.03, 0.95-1.10) and all secondary endpoints of MI, stroke, coronary revascularisation, new onset heart failure or exacerbation of pre-existing heart failure.

So the take home from this study of almost 100,000 people is that while there was a safety signal in the original registration trials for febuxostat this study in a real world setting hasn’t replicated that.

Add new comment

More Like This

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.

FDA Adds Boxed Warning to Sleep Drugs

The Food and Drug Administration (FDA) added a Boxed Warning to several sleep medications (e.g., eszopiclone, zaleplon, and zolpidem), warning rare but serious injuries may occur as a result of abnormal sleep behaviors (sleepwalking, sleep driving, and engaging in other activities while not fully awake) when taking sleep medications. These complex sleep behaviors have also resulted in deaths.

Update on Vaccines in Autoimmune Patients

Although both the disease and the treatment for it in rheumatology patients may work at cross-purposes with immunizations, only a very few vaccines are absolutely contraindicated in this population, an infectious disease specialist told rheumatologists here.

RheumNowLive On Demand: Infection Prevention and Management with Newer Agents - Jack Cush, MD

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.